These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 22180803)

  • 21. Post-kala-azar dermal leishmaniasis due to Leishmania infantum in an HIV-negative patient treated with miltefosine.
    Monge-Maillo B; Norman FF; Chamorro-Tojeiro S; Gioia F; Pérez-Molina JA; Chicharro C; Moreno J; López-Vélez R
    J Travel Med; 2022 Nov; 29(7):. PubMed ID: 34668558
    [No Abstract]   [Full Text] [Related]  

  • 22. A Luciferase-Expressing Leishmania braziliensis Line That Leads to Sustained Skin Lesions in BALB/c Mice and Allows Monitoring of Miltefosine Treatment Outcome.
    Coelho AC; Oliveira JC; Espada CR; Reimão JQ; Trinconi CT; Uliana SR
    PLoS Negl Trop Dis; 2016 May; 10(5):e0004660. PubMed ID: 27144739
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Refractory cutaneous leishmaniasis: Benefit of miltefosine].
    Guerveno C; Delavigne K; Berry A; Martin-Blondel G; Delobel P
    Med Mal Infect; 2019 Jun; 49(4):281-283. PubMed ID: 30554949
    [No Abstract]   [Full Text] [Related]  

  • 24. Assessing the Efficacy and Safety of Liposomal Amphotericin B and Miltefosine in Combination for Treatment of Post Kala-Azar Dermal Leishmaniasis.
    Ramesh V; Dixit KK; Sharma N; Singh R; Salotra P
    J Infect Dis; 2020 Feb; 221(4):608-617. PubMed ID: 31854451
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Combined topical paromomycin and oral miltefosine treatment of mice experimentally infected with Leishmania (Leishmania) major leads to reduction in both lesion size and systemic parasite burdens.
    Aguiar MG; Silva DL; Nunan FA; Nunan EA; Fernandes AP; Ferreira LA
    J Antimicrob Chemother; 2009 Dec; 64(6):1234-40. PubMed ID: 19825819
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An update on the clinical pharmacology of miltefosine in the treatment of leishmaniasis.
    Palić S; Beijnen JH; Dorlo TPC
    Int J Antimicrob Agents; 2022 Jan; 59(1):106459. PubMed ID: 34695563
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetics of Miltefosine in Children and Adults with Cutaneous Leishmaniasis.
    Castro MD; Gomez MA; Kip AE; Cossio A; Ortiz E; Navas A; Dorlo TP; Saravia NG
    Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 27956421
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Photodynamic therapy offers a novel approach to managing miltefosine-resistant cutaneous leishmaniasis.
    Cabral FV; Riahi M; Persheyev S; Lian C; Cortez M; Samuel IDW; Ribeiro MS
    Biomed Pharmacother; 2024 Aug; 177():116881. PubMed ID: 38917757
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Development of topical liposomes containing miltefosine for the treatment of Leishmania major infection in susceptible BALB/c mice.
    Kavian Z; Alavizadeh SH; Golmohamadzadeh S; Badiee A; Khamesipour A; Jaafari MR
    Acta Trop; 2019 Aug; 196():142-149. PubMed ID: 31103698
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Case Report: Miltefosine Failure and Spontaneous Resolution of Cutaneous Leishmaniasis braziliensis.
    Joseph S; Whitman TJ; Buckner FS; Cogen AL
    Am J Trop Med Hyg; 2021 May; 105(1):142-143. PubMed ID: 33970891
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cutaneous leishmaniasis (Leishmania major infection) in Dutch troops deployed in northern Afghanistan: epidemiology, clinical aspects, and treatment.
    van Thiel PP; Leenstra T; de Vries HJ; van der Sluis A; van Gool T; Krull AC; van Vugt M; de Vries PJ; Zeegelaar JE; Bart A; van der Meide WF; Schallig HD; Faber WR; Kager PA
    Am J Trop Med Hyg; 2010 Dec; 83(6):1295-300. PubMed ID: 21118937
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cutaneous leishmaniasis caused by Leishmania infantum in Southern Israel.
    Ben-Shimol S; Sagi O; Horev A; Avni YS; Ziv M; Riesenberg K
    Acta Parasitol; 2016 Dec; 61(4):855-858. PubMed ID: 27787222
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Anti-leishmanial activity of a topical miltefosine gel in experimental models of New World cutaneous leishmaniasis.
    Neira LF; Mantilla JC; Escobar P
    J Antimicrob Chemother; 2019 Jun; 74(6):1634-1641. PubMed ID: 30815688
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Drug susceptibility in Leishmania isolates following miltefosine treatment in cases of visceral leishmaniasis and post kala-azar dermal leishmaniasis.
    Bhandari V; Kulshrestha A; Deep DK; Stark O; Prajapati VK; Ramesh V; Sundar S; Schonian G; Dujardin JC; Salotra P
    PLoS Negl Trop Dis; 2012; 6(5):e1657. PubMed ID: 22629478
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Two cases of cutaneous leishmaniasis in Dutch military personnel treated with oral miltefosine.
    van der Snoek EM; Couwenberg SM; Stijnis C; Kortbeek LM; Schadd EM
    J R Army Med Corps; 2017 Feb; 163(1):68-70. PubMed ID: 26661280
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combination therapy with amphotericin-B and miltefosine for post-kala-azar dermal leishmaniasis: a preliminary report.
    Ramesh V; Avishek K; Sharma V; Salotra P
    Acta Derm Venereol; 2014 Mar; 94(2):242-3. PubMed ID: 23995012
    [No Abstract]   [Full Text] [Related]  

  • 37. Miltefosine for new world cutaneous leishmaniasis.
    Soto J; Arana BA; Toledo J; Rizzo N; Vega JC; Diaz A; Luz M; Gutierrez P; Arboleda M; Berman JD; Junge K; Engel J; Sindermann H
    Clin Infect Dis; 2004 May; 38(9):1266-72. PubMed ID: 15127339
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Advanced case of PKDL due to delayed treatment: A rare case report.
    Topno RK; Rabi Das VN; Kumar M; Madhukar M; Pandey K; Verma N; Agrawal K; Lal CS; Siddiqui NA; Bimal S; Das P
    PLoS Negl Trop Dis; 2020 Mar; 14(3):e0008052. PubMed ID: 32203500
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Miltefosine to treat cutaneous leishmaniasis caused by Leishmania tropica.
    Killingley B; Lamb LE; Davidson RN
    Ann Trop Med Parasitol; 2009 Mar; 103(2):171-5. PubMed ID: 19208301
    [No Abstract]   [Full Text] [Related]  

  • 40. Resistance of
    Regli IB; Fernández OL; Martínez-Salazar B; Gómez MA; Saravia NG; Tacchini-Cottier F
    Front Immunol; 2018; 9():3040. PubMed ID: 30622537
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.